A high-dose form of Eylea, administered less frequently, matched the original in late-stage testing, an important step in the company’s plan to defend its bestseller against competition.

The data could help Trodelvy secure a place in treatment, although a rival drug from Daiichi Sankyo and AstraZeneca will offer strong competition.

Updated data released ahead of the ESMO medical conference suggest Relay’s medicine could be more effective than others like it in treating a type of bile duct cancer.

The biotech, which has lost nearly all of its value since going public in 2020, reached a deal to sell a drug it tested in sickle cell disease to Cardurion Pharmaceuticals, a richly funded startup focused on cardiovascular research.

Fuller data from the APOLLO-B study confirm the success reported by Alnylam last month, but won’t end debate on the magnitude of the drug’s benefit.

Committee members voted 7-2 in support of the experimental medicine, which is under a closely watched FDA review. A decision on approval is expected by the end of the month.

The biotech’s Series B fundraising equips it with new cash just as it prepares to advance its first drug candidate into clinical testing.

The team behind the Seattle-based startup will launch a new company, Bonum Therapeutics, after the sale to Roche is completed.

Orbital co-founder and former Alnylam CEO John Maraganore said the startup aims to “overcome some of the shortcomings that have been there with the first generation of RNA companies.” 

Seven years after the first copycat biologic drug arrived in the U.S., expected cost savings have been modest at best. The next few years will show whether the knockoff drugs can live up to their cut-price promise.

While it plans to appeal this week’s EC decision, Illumina say it’s preparing for ‘strategic alternatives’ to its acquisition of early cancer detection firm Grail.

The company received a complete response letter, but still expects to win approval of the copycat drug in time to launch it in the U.S. next year.